Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Hutchison china meditech limited symbols : AZNCF save search
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
Published: 2023-02-28 (Crawled : 09:00) - globenewswire.com
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: -3.3%
H: 0.0%
C: -1.25%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: -1.35%
HCM | $18.41 0.88% 0.84% 58K
|
Health Technology
|
| O: 5.03%
H: 2.91%
C: 0.3%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -1.65%
H: 0.58%
C: -0.79%
year results
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Published: 2022-03-07 (Crawled : 05:00) - globenewswire.com
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: -1.8%
HCM | $18.41 0.88% 0.84% 58K
|
Health Technology
|
| O: -10.68%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
orpathys star lung cancer one cancer milestone
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: -0.02%
H: 1.33%
C: 1.33%
HCM | $18.41 0.88% 0.84% 58K
|
Health Technology
|
| O: -4.39%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
orpathys lung cancer china therapy cancer trial
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
Published: 2021-11-01 (Crawled : 06:00) - globenewswire.com
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: -0.12%
H: 1.7%
C: 1.64%
HCM | $18.41 0.88% 0.84% 58K
|
Health Technology
|
| O: -0.07%
H: 3.03%
C: 2.38%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.3%
H: 0.95%
C: 0.43%
renal trial cell carcinoma
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.